Diseases & Longevity · File 14

Dyslipidemia. ApoB and Lp(a) are the real predictors — classical LDL is not enough.

The classical cholesterol conversation — high LDL, low LDL — doesn't capture real cardiovascular risk. Sniderman et al. (JAMA Cardiology 2019) demonstrated that ApoB is direct causal predictor of cardiovascular events, superior to classical LDL. Lp(a) — independent genetic factor — affects ~20% of population and EAS 2023 recommends measuring it at least once in life. That is the real cardiovascular longevity conversation.

Why ApoB is the metric that matters, not classical LDL

Each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)) carries a single ApoB molecule. Measuring ApoB directly quantifies the number of circulating atherogenic particles — the real mechanistic determinant of arterial wall deposition. Classical LDL measures the cholesterol contained in those particles, not the particle number. That difference matters when particles are small and dense (metabolic dyslipidemia): same LDL, more particles, more risk.

Sniderman et al. (JAMA Cardiology 2019) performed comparative analysis of ApoB, non-HDL, and LDL as CV event predictors — concluding that ApoB is the direct causal predictor, superior to the others. Mendelian randomization confirms causality: genetic variants reducing ApoB proportionally reduce CV risk. EAS 2023 recommends measuring Lp(a) at least once in life in every adult — its value is predominantly genetic, stable, and an independent predictor.

Classical LDL is the old mirror. ApoB is the real photograph of the particle number circulating and depositing.
Population with elevated Lp(a)

The global weight, in numbers

Quantitative dyslipidemia data come from Mendelian randomization cohorts, lipid-lowering clinical trials, and CV event meta-analyses. These points sustain the modern conversation.

  • Elevated Lp(a)

    ~20% población

    Approximately 20% of population has Lp(a) >50 mg/dL — genetic CV risk factor, independent of LDL and only partially modifiable with classical interventions. EAS 2023 recommends measurement at least once in life.
    — EAS Consensus Statement 2022

  • ApoB > LDL as predictor

    Sniderman JAMA Cardiol 2019

    Sniderman 2019 demonstrated ApoB is direct causal predictor of CV events, superior to LDL and non-HDL — particularly in patients with metabolic dyslipidemia (T2D, obesity, metabolic syndrome).
    — Sniderman et al., JAMA Cardiol 2019

  • Statins — demonstrated effect

    ↓20-30% eventos CV

    CTT (Cholesterol Treatment Trialists) meta-analysis shows each 1 mmol/L LDL reduction with statins reduces major CV events ~22% — sustained long-term, proportional to reduction magnitude.
    — CTT Collaboration, Lancet 2010

  • PCSK9 and inclisiran

    Reducción adicional 50-60%

    PCSK9 inhibitors (evolocumab, alirocumab) and siRNA (inclisiran) reduce additional LDL 50-60% on top of maximal statin — option for patients with high residual risk, elevated Lp(a), or statin intolerance. Cardiology decision.
    — FOURIER 2017; ORION-10/11 2020

Chap. 03 · Cardiometabolic

Impact on cardiovascular trajectory and comorbidity

Dyslipidemia rarely appears alone. Its useful reading is in cluster — with HTN, T2D, obesity, and inflammaging — because they share mechanisms and common responders.

  • Familial hypercholesterolemia

    1 en 250 personas

    Familial hypercholesterolemia (FH) affects 1 in 250 — frequently underdiagnosed. FH patients have 10× higher CV risk from early ages. Family screening is priority when suspected.
    — Nordestgaard et al., Eur Heart J 2013

  • Metabolic dyslipidemia

    Patrón aterogénico común

    High triglycerides + low HDL + small dense LDL particles is the classical pattern of T2D and metabolic syndrome. LDL may be "normal" — but ApoB and atherogenic particle number are elevated.
    — ACC/AHA 2018; ESC/EAS 2019

  • Global CV risk

    Cluster > marcador aislado

    Individual CV risk depends on cluster — HTN + dyslipidemia + T2D + obesity + smoking + inflammaging — more than any isolated marker. Modern calculators (SCORE2, ASCVD) integrate multiple factors; in longevity, ApoB, Lp(a), hsCRP are added.
    — ESC SCORE2 2021

  • Statins and longevity

    Beneficio en prevención secundaria sólido

    Statin benefit in secondary prevention is beyond discussion. In primary prevention, decision is individualized by baseline risk — where ApoB, Lp(a), and longevity biomarkers improve precision vs only classical LDL.
    — CTT 2010; USPSTF 2022

What we don't offer — and what we do

Wellness Care does not replace the cardiologist in deciding to prescribe statins, ezetimibe, PCSK9 inhibitors, or inclisiran. Choice, titration, and follow-up of the lipid-lowering drug are the specialist's competence. What we do is what the conventional system rarely does well: the advanced lipid reading (ApoB, Lp(a), non-HDL, particle analysis when indicated), the cardiometabolic cluster context, and integration with longevity biomarkers.

We evaluate patients with family history of dyslipidemia or early CV event, persistently elevated LDL, low HDL with high TG, suspected familial hypercholesterolemia, already treated with statins but with residual risk, or suspected elevated Lp(a) never measured. Integrated intervention — lifestyle, optimization of cardiology management when applicable, addressing the cluster — is what adds real value.

Classical LDL is the first layer. ApoB and Lp(a) are the mechanistic photograph — and should be measured at least once in life in every adult.
How we measure it

How dyslipidemia is evaluated
at Wellness Care

Advanced lipid profile + cardiometabolic cluster + inflammaging, under cardiology coordination when clinically indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern dyslipidemia conversation — ApoB as causal predictor, genetic Lp(a), statins, and new therapies.

«ApoB es el predictor causal directo de eventos cardiovasculares — superior al LDL clásico y al no-HDL en el análisis comparativo.»
JAMA Cardiology · 2019
Sniderman et al., JAMA Cardiol 2019
ApoB > LDL como predictor
«Lp(a) debe medirse al menos una vez en la vida en todo adulto — factor genético independiente que afecta al ~20% de la población.»
EAS · 2022
EAS Consensus Statement 2022
Recomendación Lp(a)
«Cada 1 mmol/L de reducción de LDL con estatinas reduce eventos CV mayores ~22% — efecto sostenido a largo plazo, proporcional a la magnitud.»
Lancet · 2010
CTT Collaboration, Lancet 2010
Meta-análisis CTT

Frequently asked questions about dyslipidemia

The most recurrent questions about dyslipidemia, ApoB vs LDL, Lp(a), statins, and why longevity medicine changes the lipid reading.

01

Why measure ApoB if I already have LDL?

Because ApoB quantifies circulating atherogenic particle number — the direct mechanistic determinant of arterial wall deposition.

LDL measures contained cholesterol, not particles.

In patients with metabolic dyslipidemia (T2D, obesity, metabolic syndrome), particles are small and dense: same LDL, more particles, more risk.

ApoB captures that phenotype.

Sniderman 2019 demonstrated it's a superior predictor.

02

What is Lp(a) and why does it matter?

Lp(a) is a genetically determined lipoprotein — its level is stable throughout life and not significantly modified by diet or conventional statins.

It's an independent CV risk factor:

· Affects ~20% of population with values >50 mg/dL
· EAS 2023 recommends measuring it at least once in life

Specific treatments under investigation:

· Pelacarsen (antisense ASO)

03

When are statins indicated in primary prevention?

Decision is individualized — depends on:

· Global CV risk calculated with SCORE2 (Europe) or ASCVD (US)
· Age, comorbidities
· ApoB, Lp(a) as refiners
· Patient preferences

ESC/EAS 2019 guidelines recommend statins in patients with 10-year CV risk:

· ≥10% (high)
· ≥7.5% (intermediate if refined by biomarkers)

Benefit is proportional to baseline risk and to LDL/ApoB reduction magnitude.

Decision belongs to the cardiologist.

04

What lifestyle changes really reduce ApoB?

Interventions with demonstrated effect:

· Mediterranean / DASH diet with unsaturated fats → -10 to -20% LDL/ApoB
· Glycemic load reduction and simple sugars → reduces TG and small dense particles
· Weight loss if overweight → -5% weight reduces LDL ~5%
· Regular aerobic exercise → raises HDL, reduces TG, improves ApoB
· Alcohol restriction
· Stress and sleep management

Combined effect can be significant, but does not replace medication when it is indicated.

05

When should I consult?

A structured assessment is worthwhile if:

· Family history of dyslipidemia or early CV event (<60)
· Persistently elevated LDL
· Low HDL with high TG
· Suspected familial hypercholesterolemia
· Lp(a) never measured
· Already taking statins but want to confirm optimal management
· Want to understand your CV trajectory before symptoms

The assessment complements the cardiologist — does not replace them.

What LDL misses

Classical LDL is the first layer. ApoB and Lp(a) are the real mechanistic photograph — and should be measured at least once in life in every adult.

Measure ApoB, Lp(a), and non-HDL at least once in life, contextualize within the cardiometabolic cluster, integrate with longevity biomarkers, and coordinate with cardiology — that changes the lipid conversation.

Family history or persistently elevated LDL?

Book an advanced lipid and cardiovascular longevity assessment

We evaluate advanced lipid profile (ApoB, Lp(a), non-HDL, LDL particles), inflammaging (hsCRP), metabolic profile, global cardiovascular risk, endothelial function when applicable. The assessment does not replace cardiology — it complements with biomarkers the conventional system rarely orders.

Book advanced lipid assessment